The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pressure to select
Shingo Yamaguchi +2 more
doaj +3 more sources
Adapting drug approval pathways for bacteriophage-based therapeutics
The global rise of multi-drug resistant bacteria has resulted in the notion that an antibiotic apocalypse is fast approaching. This has led to a number of well publicized calls for global funding initiatives to develop new antibacterial agents. The long
Callum Cooper +3 more
doaj +2 more sources
Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans. [PDF]
Summary Background Poor translation between in vitro and clinical studies due to the cells/humans discrepancy in drug target perturbation effects leads to safety failures in clinical trials, thus increasing drug development costs and reducing patients ...
Park M, Kim D, Kim I, Im SH, Kim S.
europepmc +2 more sources
From Concept to Regulatory Drug Approval: Lessons for Theranostics. [PDF]
Radiopharmaceutical therapy is an emerging treatment modality that has demonstrated increasing importance as a significant component in the treatment of cancer.
Perera M, Morris MJ.
europepmc +2 more sources
FDA Drug Approval and the Ethics of Desperation. [PDF]
In justifying the accelerated approval of aducanumab (Aduhelm; Biogen), US Food and Drug Administration (FDA) officials emphasized that many patients with Alzheimer disease and their families “made it clear that they are willing to accept the trade-off ...
Largent EA, Peterson A, Lynch HF.
europepmc +2 more sources
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap. [PDF]
Improvements in multiple myeloma treatments have extended patient survival to a decade or more. Treatment response rates >90% have introduced new challenges for drug development, including a need for early endpoints with greater sensitivity.
Landgren O, Devlin SM.
europepmc +2 more sources
Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'. [PDF]
Background The magnitude of clinical benefit of solid cancer drugs can be standardly assessed via the Magnitude of Clinical Benefit Scale (MCBS) developed by the European Society for Medical Oncology (ESMO).
Grössmann N +3 more
europepmc +2 more sources
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. [PDF]
International drug regulators use conditional drug approval mechanisms to facilitate faster patient access to drugs based on a lower evidentiary standard typically required of drug approvals. Faster and earlier access is justified by limiting eligibility
McPhail M, Weiss E, Bubela T.
europepmc +2 more sources
An Analysis of New Drug Examination and Approval System of PRC [PDF]
This paper analyzes the new drug examination and approval systems before and after the Measures was amended in 2007 and evaluates the effectiveness of the 2007 Amendment.
Sun, Xiaopu
core +6 more sources
Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go. [PDF]
Purpose: To discuss the clinical trial results leading to the FDA approval of anti-complement therapies for geographic atrophy (GA), perspectives on functional data from the GA clinical trials, and how lessons from the FDA approval may guide future ...
Csaky KG +3 more
europepmc +2 more sources

